Evidence map›Paper›PMID 41574738›Full record

ArticleJournal of medicinal chemistry2026

Short-Chain and Long-Chain Fatty Acid-Containing Platinum-Acridine Anticancer Prodrugs: Exploiting Alternative Mechanisms of Cellular Internalization.

David J Halatek, Sarah A Bo, Samuel M Feder, Lilly Wolf, Dylan J Coffin, Lauren A Sapp, Glen S Marrs, Beatriz M Fontoura, Bradley T Jones, Ulrich Bierbach

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

David J HalatekDepartment of Chemistry, Wake Forest University, Wake Downtown Campus, Winston-Salem, North Carolina 27101, United States.ORCID 0009-0005-1203-8289
Sarah A BoDepartment of Chemistry, Wake Forest University, Wake Downtown Campus, Winston-Salem, North Carolina 27101, United States.ORCID 0009-0007-4701-0520
Samuel M FederDepartment of Chemistry, Wake Forest University, Wake Downtown Campus, Winston-Salem, North Carolina 27101, United States.ORCID 0009-0002-2184-941X
Lilly WolfDepartment of Chemistry, Wake Forest University, Wake Downtown Campus, Winston-Salem, North Carolina 27101, United States.
Dylan J CoffinDepartment of Chemistry, Wake Forest University, Wake Downtown Campus, Winston-Salem, North Carolina 27101, United States.ORCID 0009-0007-3172-9688
Lauren A SappDepartment of Chemistry, Wake Forest University, Wake Downtown Campus, Winston-Salem, North Carolina 27101, United States.
Glen S MarrsDepartment of Biology, Wake Forest University, Winston-Salem, North Carolina 27109, United States.
Beatriz M FontouraDepartment of Chemistry, Wake Forest University, Winston-Salem, North Carolina 27109, United States.ORCID 0000-0003-0533-2066
Bradley T JonesDepartment of Chemistry, Wake Forest University, Winston-Salem, North Carolina 27109, United States.
Ulrich BierbachDepartment of Chemistry, Wake Forest University, Wake Downtown Campus, Winston-Salem, North Carolina 27101, United States.ORCID 0000-0001-5658-7662

Funding

Tumor Tissue CoreP30CA012197 · NCI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI Ruben A. Mesa · 1985 to 2026
$55.4M
NCI NIH HHS P30 CA012197
6 · The paper itself

Abstract

Platinum-acridine hybrid agents (PAs) represent a mechanistically unique class of DNA-targeted anticancer compounds with superior potency compared to cisplatin, but systemic toxicity has limited their clinical utility. To address this, we have developed platinum(IV) prodrugs of PAs for controlled reductive activation in tumor tissues. Short-chain fatty acid (SCFA) containing derivatives demonstrated nanomolar cytotoxicity in cancer cells expressing human multidrug and toxin extrusion protein 1 (hMATE1), consistent with rapid transporter-dependent uptake. Long-chain fatty acid (LCFA)-modified derivatives were less potent than the SCFA-based prodrugs in hMATE1

Indexed as

AcridinesAntineoplastic AgentsFatty AcidsOrganoplatinum CompoundsProdrugsCell Line, TumorDrug Screening Assays, AntitumorHumansStructure-Activity RelationshipAcridinesAntineoplastic AgentsFatty AcidsOrganoplatinum CompoundsProdrugs

Identifiers

PMID41574738
PMCPMC13378528

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.